P120 catenin is a key effector of a Ras-PKCε oncogenic signaling axis

Oncogene

Volumn 33, Issue 11, 2014, Pages 1385-1394

  Dann, S G ^a   Golas, J ^a   Miranda, M ^a   Shi, C ^a   Wu, J ^a   Jin, G ^a   Rosfjord, E ^a   Upeslacis, E ^a   Klippel, A ^a  

^a PFIZER INC   (United States)

Author keywords

drug discovery; epithelial to mesenchymal transition; p120 catenin; protein kinase C; triple negative breast cancer

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINO ACID; BETA CATENIN; CATENIN; PF 5263555; PROTEIN KINASE C EPSILON; PROTEIN KINASE C INHIBITOR; PROTEIN P120; RAS PROTEIN; SERINE; SHORT HAIRPIN RNA; STABLE ISOTOPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CELL STRUCTURE; CONTACT INHIBITION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; EPITHELIUM CELL; FEMALE; GENE ACTIVATION; GENE LOSS; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MESENCHYME CELL; MOUSE; NONHUMAN; ONCOGENE H RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT;

CATENINS; CRK-ASSOCIATED SUBSTRATE PROTEIN; ONCOGENES; PHOSPHORYLATION; PROTEIN KINASE C-EPSILON; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84896395145     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.91     Document Type: Article

References (40)

1. Mackay HJ, Twelves CJ. Targeting the protein kinase C family: are we there yet? Nat Rev Cancer 2007; 7: 554-562. (Pubitemid 46985395)
2. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007; 7: 281-294. (Pubitemid 46480971)
3. Gorin MA, Pan Q. Protein kinase C epsilon: an oncogene and emerging tumor biomarker. Mol Cancer 2009; 8: 9.
4. Mischak H, Goodnight JA, Kolch W, Martiny-Baron G, Schaechtle C, Kazanietz MG et al. Overexpression of protein kinase C-delta and-epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J Biol Chem 1993; 268: 6090-6096. (Pubitemid 23099293)
5. Cacace AM, Guadagno SN, Krauss RS, Fabbro D, Weinstein IB. The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts. Oncogene 1993; 8: 2095-2104. (Pubitemid 23226942)
6. Hafeez BB, Zhong W, Weichert J, Dreckschmidt NE, Jamal MS, Verma AK. Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. Cancer Res 2011; 71: 2318-2327.
7. Benavides F, Blando J, Perez CJ, Garg R, Conti CJ, Digiovanni J et al. Transgenic overexpression of PKCepsilon in the mouse prostate induces preneoplastic lesions. Cell Cycle 2011; 10: 268-277.
8. Leask A, Shi-Wen X, Khan K, Chen Y, Holmes A, Eastwood M et al. Loss of protein kinase Cepsilon results in impaired cutaneous wound closure and myofibroblast function. J Cell Sci 2008; 121(Pt 20): 3459-3467.
9. Saurin AT, Durgan J, Cameron AJ, Faisal A, Marber MS, Parker PJ. The regulated assembly of a PKCepsilon complex controls the completion of cytokinesis. Nat Cell Biol 2008; 10: 891-901.
10. Ivaska J, Vuoriluoto K, Huovinen T, Izawa I, Inagaki M, Parker PJ. PKCepsilon-mediated phosphorylation of vimentin controls integrin recycling and motility. EMBO J 2005; 24: 3834-3845. (Pubitemid 41637991)
11. Tuomi S, Mai A, Nevo J, Laine JO, Vilkki V, Ohman TJ et al. PKCepsilon regulation of an alpha5 integrin-ZO-1 complex controls lamellae formation in migrating cancer cells. Sci Signal 2009; 2: ra32.
12. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
13. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009; 119: 1429-1437.
14. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N et al. A gene expression signature associated with 'K-Ras addiction' reveals regulators of EMT and tumor cell survival. Cancer Cell 2009; 15: 489-500.
15. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007; 1: 84-96. (Pubitemid 46776616)
16. Leenders F, Mopert K, Schmiedeknecht A, Santel A, Czauderna F, Aleku M et al. PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. EMBO J. 2004; 23: 3303-3313. (Pubitemid 39209154)
17. Prashad AS, Wang D, Subrath J, Wu B, Lin M, Zhang MY et al. C-5 substituted heteroaryl-3-pyridinecarbonitriles as PKCtheta inhibitors: part II. Bioorg Med Chem Lett 2009; 19: 5799-5802.
18. Cameron AJ, Escribano C, Saurin AT, Kostelecky B, Parker PJ. PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nat Struct Mol Biol 2009; 16: 624-630.
19. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R et al. Inhibitor hijacking of Akt activation. Nat Chem Biol 2009; 5: 484-493.
20. Weinstein IB. The origins of human cancer: molecular mechanisms of carcino-genesis and their implications for cancer prevention and treatment-twenty-seventh G.H.A. Clowes memorial award lecture. Cancer Res 1988; 48: 4135-4143.
21. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011; 145: 926-940.
22. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2012; 18: 74-82.
23. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 2009; 69: 2287-2295.
24. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009; 69: 4116-4124.
25. Brown MV, Burnett PE, Denning MF, Reynolds AB. PDGF receptor activation induces p120-catenin phosphorylation at serine 879 via a PKCalpha-dependent pathway. Exp Cell Res 2009; 315: 39-49.
26. Reynolds AB, Roczniak-Ferguson A. Emerging roles for p120-catenin in cell adhesion and cancer. Oncogene 2004; 23: 7947-7956. (Pubitemid 39468853)
27. Xia X, Carnahan RH, Vaughan MH, Wildenberg GA, Reynolds AB. p120 serine and threonine phosphorylation is controlled by multiple ligand-receptor pathways but not cadherin ligation. Exp Cell Res 2006; 312: 3336-3348. (Pubitemid 44389941)
28. Ozawa M, Ohkubo T. Tyrosine phosphorylation of p120(ctn) in v-Src transfected L cells depends on its association with E-cadherin and reduces adhesion activity. J Cell Sci 2001; 114(Pt 3): 503-512.
29. Dohn MR, Brown MV, Reynolds AB. An essential role for p120-catenin in Src-and Rac1-mediated anchorage-independent cell growth. J Cell Biol 2009; 184: 437-450.
30. Soto E, Yanagisawa M, Marlow LA, Copland JA, Perez EA, Anastasiadis PZ. p120 catenin induces opposing effects on tumor cell growth depending on E-cadherin expression. J Cell Biol 2008; 183: 737-749.
31. Shibata T, Kokubu A, Sekine S, Kanai Y, Hirohashi S. Cytoplasmic p120ctn regulates the invasive phenotypes of E-cadherin-deficient breast cancer. Am J Pathol 2004; 164: 2269-2278. (Pubitemid 38669372)
32. Bellovin DI, Bates RC, Muzikansky A, Rimm DL, Mercurio AM. Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. Cancer Res 2005; 65: 10938-10945. (Pubitemid 41713362)
33. Paredes J, Correia AL, Ribeiro AS, Milanezi F, Cameselle-Teijeiro J, Schmitt FC. Breast carcinomas that co-express E-and P-cadherin are associated with p120-catenin cytoplasmic localisation and poor patient survival. J Clin Pathol 2008; 61: 856-862. (Pubitemid 351969733)
34. Doehn U, Hauge C, Frank SR, Jensen CJ, Duda K, Nielsen JV et al. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol Cell 2009; 35: 511-522.
35. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG. Ras-and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest 2009; 119: 252-266.
36. Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM et al. Genome and transcriptome sequencing in prospective refractory metastatic triple negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther 2013; 12: 104-116.
37. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131: 1109-1123. (Pubitemid 350235025)
38. Sternberger M, Schmiedeknecht A, Kretschmer A, Gebhardt F, Leenders F, Czauderna F et al. GeneBlocs are powerful tools to study and delineate signal transduction processes that regulate cell growth and transformation. Antisense Nucleic Acid Drug Dev 2002; 12: 131-143. (Pubitemid 34815925)
39. Wu J, Shakey Q, Liu W, Schuller A, Follettie MT. Global profiling of phosphopeptides by titania affinity enrichment. J Proteome Res 2007; 6: 4684-4689.
40. Czauderna F, Santel A, Hinz M, Fechtner M, Durieux B, Fisch G et al. Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res 2003; 31: e127.